BreastMark specifications


Unique identifier OMICS_12525
Name BreastMark
Interface Web user interface
Restrictions to use None
Computer skills Basic
Stability Stable
Maintained Yes


  • Primates
    • Homo sapiens


  • person_outline Stephen F. Madden <>

Publication for BreastMark

BreastMark in publications

PMCID: 5933288
DOI: 10.1080/20013078.2018.1461450

[…] released from each cell variant. evs were characterized by immunoblotting, tem and nta. olink proteomics was performed on cell lines and their respective evs. kaplan–meier plots were created using breastmark. immunoblots and elisas were utilized to validate the proteomic results (macrophage colony-stimulating factor (csf-1) and carbonic anhydrase 9 (caix)). cells were treated with deferoxamine […]

PMCID: 5884656
PMID: 29644001
DOI: 10.18632/oncotarget.24590

[…] high bag3 mrna expression which significantly correlated with reduced recurrence free survival (rfs) [p =0.026, hr = 1.41, cl (1.04–1.91)] (figure ). further survival analysis was carried out using breastmark, an online integrated resource [] to allow evaluation of genes that are associated with survival outcome in breast cancer. no significant correlation between bag3 mrna and rfs was observed […]

PMCID: 5877554
PMID: 29495625
DOI: 10.3390/ijms19030693

[…] in er-negative [] and her2e [] tumors have been previously reported using the web-based platform kmplotter [] while er-positive tumors had a better prognosis []. investigating further the results of breastmark and kmplotter web platforms, survival analysis showed that pooled and luminal tumors with high levels of gja1 mrna were associated with a better prognostic (hazard ratio < 1), although […]

PMCID: 5507892
PMID: 28701793
DOI: 10.1038/s41598-017-05727-w

[…] also showed that higher atp5g1 expression was associated with reduced disease free survival (dfs, which is the same as rfs) in erα+ breast cancer patients in ireland ( we note that all data in both databases are from primary tumors. based on our lcc9 and ly2 cell experiments, we would expect that breast cancer patients […]

PMCID: 5502327
PMID: 28740830
DOI: 10.3389/fonc.2017.00139

[…] in cancer., to verify whether correlations between mcu complex components expression, tumor progression, and prognosis exist, different approaches have been used. in a study by hall et al., the breastmark algorithm, which integrates many dna microarray experiments for which clinical data are available, was interrogated to determine the relationship between expression of mcu and micu1 […]

To access a full list of publications, you will need to upgrade to our premium service.

BreastMark institution(s)
Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland; UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland
BreastMark funding source(s)
The Science Foundation Ireland Strategic Research Cluster, Molecular Therapeutics for Cancer Ireland; the FP7 Collaborative Health programme, RATHER

BreastMark reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review BreastMark